Background
Soft tissue sarcomas encompass a diverse group of mesenchymal tumors, some of which have unique biology and epidemiology within the pediatric age group. Rhabdomyosarcomas are the best characterized and studied with relatively good sensitivity to both chemotherapy and radiotherapy. To distinguish the other broad category of pediatric tumors derived from connective tissue, the cumbersome term, nonrhabdomyosarcoma soft tissue sarcomas (NRSTS), has been coined. Many, but not all NRSTS, share characteristics with adult-type soft tissue sarcomas (STS) leading to a wealth of treatment principles that cross the age spectrum. But because of developmental toxicities especially from radiotherapy, there are considerable modifications in treatment philosophy with the management of NRSTS. Unlike rhabdomyosarcoma, where well conducted randomized trials have progressively refined the dose, fractionation, and volume of radiotherapy in a risk adapted manner, the evidence for optimal management of NRSTS is still evolving. Relative to the adult management of STS, the oncologist needs to be more mindful of the late effects of treatment, which include concerns for normal growth, fertility, and risk for secondary malignancy. But at what age should STS be treated more aggressively with radiotherapy is difficult to know as NRSTS clinical trials extend eligibility to young adults. This review will provide an overview of evolving knowledge regarding NRSTS while focusing on the radiotherapeutic aspects.
Epidemiology
Soft tissue sarcomas represent 6-7 % of all pediatric cancers (defined as those occurring before age 20 years). Of these, 40 % are rhabdomyosarcoma and 60 % are NRSTS [1] [2] [3] . The USA's Surveillance, Epidemiology, and End Results (SEER) program provides some of the most comprehensive cancer epidemiologic data available [4] . Of the European Tumor Registries, only data published from Germany have sufficient detail to distinguish rhabdomyosarcoma from NRSTS [5] . Overall, NRSTS comprise approximately 3-3.5 % of all pediatric cancers with 550 to 600 new cases diagnosed each year in the USA. The incidence rate over time has remained steady in the range of six to eight cases per million population. In Germany, the incidence rate is slightly less at five cases per million persons. Data from SEER based on the time period 1975-1995 suggest that NRSTS has had a propensity to dominate in older pediatric age groups (10-14 years and 15-19 years, specifically) as part of the incidence curves for STS leading into adulthood. In fact, clinical features for soft tissue sarcomas are similar between children and adults, except that survival rates diminish for patients over age 50 years [6] . See Fig. 1 , depicting the distribution of STS subtypes, location of disease, and staging by 10-year age intervals.
The survival of patients with NRSTS is dependent on the histologic subtype to a certain degree. Figure 2 depicts the 5-year survival rates by histology across the age spectrum. Within the pediatric age group, patients with fibrosarcomas, synovial cell sarcomas tend to have better survivals than malignant peripheral nerve sheath tumors and extra-osseous peripheral neuroectodermal tumors. Although the trends in survival improvements within the SEER database are hard to decipher as to differences between rhabdomyosarcoma and NRSTS, pediatric soft tissue sarcomas have been associated with improving survival over time. Specifically, for patients younger than 16 years of age who were diagnosed with a soft tissue sarcoma in 1975-1977, the adjusted 5-year survival was 61 %. For those diagnosed between 1996 and 2004, there was a statistically significant improvement in the 5-year survival to 74 % [7, 8] . But, in a SEER comparison of the time periods 1975 to 1984 with 1985 to 1994, there was no improvement in survival rates for NRSTS [4] . In addition, there have been relatively few patients with NRSTS who have been enrolled in cooperative group clinical trials. While the Children's Oncology Group (COG) ARST0332 trial closed in February 2012 with 588 patients enrolled over 5 years, prior to that time less than 200 patients had been enrolled in only three prospective clinical trials in the USA [9, 10] . ARST0332 was a comprehensive study of NRSTS in the USA across different stages and risk strata, representing current treatment concepts, and will be discussed further below.
Given the common clinical features of many pediatric and adult STS, it is important to note that these sarcomas are overall rare with approximately 9,000-9,500 cases diagnosed in the USA annually (less than 1 % of malignant tumors). In those diagnosed with an STS across the age spectrum, approximately one third die from the disease. Sites of sarcoma development are distributed in the following way: 46 % lower extremity, 19 % torso, 14 % upper extremity, 13 % retroperitoneum, and 8 % head and neck. In general, sarcomas tend to be locally infiltrative and nodal metastases are uncommon, especially for small, low-grade tumors. There is some tendency for regional nodal metastases in the synovial cell and epithelioid histological subtypes (as there is for rhabdomyosarcomas). Overall, the most common site for distant metastatic disease is the lung. In comparing pediatric NRSTS and adult STS, the most common histologic subtype for both groups is synovial sarcoma. Similarly to adult sarcomas, pediatric NRSTS tend to occur in the extremities or trunk and present as a mass or other symptoms due to invasion of an adjacent structure.
Pathology
Many of the pediatric NRSTSs have characteristic cell types. The World Health Organization classification utilizes lines of differentiation in order to categorize NRSTS tumors into adipocytic, fibroblastic/myofibroblastic, fibrohistiocytic, smooth muscle, pericytic (perivascular), and vascular types, as well as tumors of uncertain differentiation [11] . NRSTSs often are difficult for pathologists to classify, and there is wide intra-observer variation [12] . Furthermore, a reasonable number of NRSTSs display no cellular differentiation and care therefore referred to as undifferentiated sarcomas or sarcomas not otherwise specified. Of the poorly differentiated STSs, pleomorphic sarcoma is now the preferred term for malignant fibrous histiocytoma, which tends to be more common in adults than in children. Immunohistochemistry and molecular genetics are often utilized to better characterize soft tissue sarcomas.
For most children with NRSTS, the etiology or cause of tumor development is uncertain. Some cases may be linked with prior radiation exposure, chemical exposure, iatrogenic or disease-causes immunosuppression, and neurofibromatosis, with the latter group having a 2-16 % risk of developing a malignant peripheral nerve sheath tumor (MPNST) in their lifetime. The development of sarcomas in patients with neurofibromatosis has been associated with chromosome 17 deletions [1] . Furthermore, familial Li-Fraumeni syndrome, with deletions affecting the p53 tumor suppressor gene, has been linked to the development of both rhabdomyosarcoma and NRSTS. Finally, gastrointestinal stromal tumors are of particular interest, albeit rare in the pediatric population, as its associated c-kit oncogene mutation has been successfully treated with imatinib, a prototype tyrosine kinase inhibitor [13] .
While not yet tested in pediatric NRSTS, there are a variety of other molecular targets and associated agents under investigation in adult soft tissue sarcomas including platelet derived growth factor receptor-A (sunitinib), Raf kinase (sorafenib), mTOR (rapamycin), vascular endothelial growth factor (bevacizumab), heat shock proteins, hedgehog, histone deacetylase, and nucleotide excision repair [14] . Table 1 represents a comprehensive list of NRSTS histologies and associated chromosomal aberrations and/or genes involved [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] .
This expanding knowledge of the molecular pathogenesis of NRSTS is worth highlighting as this will ultimately be a source for future refinements in risk stratification and treatment. As a first example, primitive neuroectodermal tumors, which are both bone and soft tissue tumors, have a characteristic molecular translocation between the EWS and FLI1 genes on chromosome 22 and chromosome 11, respectively. This translocation, t (11;22)(q24;q12), forms the EWS/FLI1 gene and leads to activation of an aberrant proliferation program, which then causes malignant transformation. There are alternative forms of the EWS/FLI1 gene that exist secondary to variations in the locations of the EWS and FLI1 genomic breakpoints. The most common form is type 1 (60 %), in which the first seven exons of EWS join to exons 6-9 of FLI1. Type 2 represents 25 % of the various forms and includes FLI1 exon 5. Overall, type 1 fusion is associated with a significantly better prognosis, as it encodes a less active chimeric transcription factor. Synovial sarcomas are soft tissue sarcomas in which approximately 30 % occur in patients less than 20 years of age. These tumors tend to develop on the extremities and the most common site of metastasis is the lung. Synovial sarcomas harbor a unique chromosome translocation in which the SYT gene on chromosome 18 is translocated with the SSX gene on chromosome X. Pathologic subtypes of synovial sarcomas include mixed epithelial and spindle cell. Some of the poor prognostic factors include stage III/IV disease, Adapted from Skubitz KM and D'Adamo [87] and from [14] . Gene symbols are those provided in the Human Genome Nomenclature Database (www.genenames.org). Previous names of genes are given in parentheses truncal location, degree of necrosis and mitosis, and elevated age at diagnosed. Synovial sarcomas are typically more responsive to chemotherapy as compared to other sarcomas. Desmoplastic small round cell tumor is a histological variant of a small round blue cell tumor and is distinguished by the presence of translocation t(11;22)(p13;q12), which has been characterized as a fusion of the WT1 and EWS genes. These tumors have a male predominance and most frequently involve the abdomen, pelvis, or tissues around the testes. Desmoplastic small round cell tumors invade locally but may spread to the lungs or elsewhere. The lesions are typically PET positive, which is useful for staging purposes. There is an overall poor prognosis, but these tumors tend to respond to multi-agent chemotherapy (with frequent relapses). The role of radiotherapy in the treatment of desmoblastic small round cell tumors is unclear at this time.
Epithelioid sarcoma is a type of NRSTS with uncertain histogenesis which displays multilineage differentiation and is secondary to inactivation of the SMARC/INI1 gene. Typical presentation is a slow growing firm nodule based in the deep soft tissue. Prognosis differs based on site of origin of the tumor, as the distal type, involving the hand, has a more benign course overall. The proximal type predominantly affects adults and involves the axial skeleton and proximal sites. This type is highly aggressive and has a propensity for lymph node metastases. One series of 30 pediatric patients with epithelioid sarcoma, with median age at presentation of 12 years, reported responses to chemotherapy in 40 % of patients using sarcoma-based regimens. Sixty percent of these patients were alive 5 years after initial diagnosis.
MPNST are a type of NRSTS associated with neurofibromatosis 1 (NF1), but may also occur sporadically. In NF1 patients, 2-16 % of nodular plexiform neurofibromas will transform into MPNSTs. Favorable features include localized disease, small tumor size, lower stage, and tumor location on an extremity as the primary site. Furthermore, there are variable reports noting that non-NF1 cases have a better prognosis. Overall, unresectable or metastatic disease has a poor prognosis while chemotherapy is associated with limited responses.
Presentation, workup, and staging
The majority of NRSTSs present as painless swelling; however, some may also present with signs and symptoms of neurologic abnormality from nerve compression, vascular compression, or bowel dysfunction when arising from the retroperitoneum. Swelling as the first symptom occurs in 75 % of patients with NRSTS. While it is not surprising, the increasing tumor size, higher stage, and nodal spread are poor prognostic factors, the time interval from first symptom to diagnosis appears to be inversely correlated with survival for pediatric sarcomas [32] . Systemic symptoms such as fever, weight loss, or anorexia are rare. However, there is an association of hypoglycemic hypophosphatemic rickets with hemangiopericytoma and hyperglycemia with lung fibrosarcoma. One may speculate that such observations may one day be explained by juxtaposed deleted genes on a chromosomal segment encoding for a metabolic pathway and a tumor suppressor function. The typical workup starts with a plain radiograph of the affected area looking for evidence of soft tissue mass, calcification, and/or destruction of adjacent bone. Computed tomography (CT) and magnetic resonance imaging (MRI) are critical radiographic studies when evaluating the tumor extent, pattern of infiltration, and adjacent structures, as well as to allow for surgical and radiotherapeutic planning of treatment. To complete staging evaluation, chest radiograph, and thoracic CT scanning are commonly pursued in order to visualize the most common distant metastatic site, the lungs [33] [34] [35] [36] [37] [38] . There has recently been an increased use of metabolic scanning techniques, including thallium and positron emission tomography (PET). PET scans determine glucose metabolism rate in the tumor and may be utilizing to correlate with tumor grade and to monitor therapeutic response [39, 40] .
Staging pediatric NRSTS can be accomplished using the 2010 American Joint Committee on Cancer Staging (Table 2) [41], which incorporates the following: tumor size (T1≤5 cm, T2>5 cm) and depth (a0superficial, b0deep), nodal involvement (N), distant metastases (M), and histologic grade (G). It is well-known that tumor size and resectability are important characteristics in predicting outcomes for pediatric NRSTS. T1a  N0  M0  G1  T1b  N0  M0  G1  Stage IB  T2a  N0  M0  G1  T2b  N0  M0  G1  Stage IIA  T1a  N0  M0  G2  T1b  N0  M0  G2, 3  Stage IIB  T2a  N0  M0  G2  T2b  N0  M0  G2  T2b  N0  M0  G2  Stage III  T2a, T2b  N0  M0  G3  Any T  N1  M0 Any G Stage IV Any T Any N M1 Any G T1 is defined as tumor less than or equal to 5 cm in greatest length with T2 greater than 5 cm. The "a" designated a superficial tumor as located exclusively above the superficial fascia without invasion of the fascia; "b" designates a deep tumor is located either exclusively beneath the superficial fascia, superficial to the fascia with invasion of or through the fascia, or both superficial yet beneath the fascia. N1 and M1 are positive findings for nodal or distant metastatic spread. The G designates a grade on a three-point scale of G1 well differentiation; G2 moderate differentiation, G3 poor or undifferentiation. Source: Edge et al. [88] But rather than TNM staging, risk stratification is more commonly employed for NRSTS. A retrospective analysis from St. Jude Children's Research Hospital in 2002 identified a statistically significant difference in 5-year survival probability in patients based on surgical risk stratification into three distinct groups: (1) grossly resected non-metastatic disease (89 % 5-year survival); (2) initially unresectable, nonmetastatic disease (56 % 5-year survival), and (3) metastatic disease (15 % 5-year survival) [42] [43] [44] . Overall, adverse risk factors include metastatic disease, tumor size >5 cm, highgrade histology, positive surgical margins, intra-abdominal primary tumor site, and omission of postoperative radiotherapy in localized disease (see Fig. 3 ).
Tumor grading
Histologic grading has very important implications in predicting outcome of patients with NRSTS. Furthermore, it is crucial that clinicians understand the criteria and uncertainties associated with grading, as many treatment decisions depend on pathologic interpretation. There are primarily two grading systems for pediatric NRSTSs that we will focus on for this review. The first system, developed by the Pediatric Oncology Group (POG), labels tumors in the following way: grade 1, tumors with low tendency for malignancy; grade 2, tumors with fewer than five mitoses per ten high-powered fields or less than 15 % geographic necrosis; and grade 3, tumors known to be clinically aggressive by virtue of histologic diagnosis and with more than four mitoses per ten high-powered fields or more than 15 % geographic necrosis (see Table 3 ) [45] . One review of this POG grading system found a 73 % mortality in grade 3 lesions and 15 % mortality in grade 1 and 2 tumors [46] . The second commonly used grading system, which is predominantly used worldwide, is the French Federation of Cancer Centres (FNCLCC) system, despite being largely based on adult cases [47] . This is a three-tiered grading system that has a point scoring system based on tumor histology, necrosis, and mitosis that has clinical appeal secondary to its reproducibility and simplicity (see Tables 4 and 5 ) [48] . The main criticism is that there are some histologic subtypes (e.g., pleomorphic undifferentiated sarcoma, alveolar soft parts sarcoma) that do not have characteristics which recapitulate normal tissues and cannot be easily scored in terms of differentiation.
Recently, Khoury et al. directly compared the POG and FNCLCC grading systems for pediatric NRSTSs [49] . In this study, 130 tumors were graded using both the POG and FNCLCC grading systems, and it was determined that both grading systems were equally effective in predicting eventfree survival. Interestingly, the POG system appeared to upgrade tumors in comparison to the FNCLCC system, and a conclusion was made that the FNCLCC system was superior to the POG system for tumors of intermediate grade. Furthermore, the mitotic index cutoff was noted to be a highly relevant grading parameter needing further study in a prospective trial.
There are certain types of pediatric NRSTS that have a low potential for metastasis, and surgery alone is the mainstay of therapy. These types include infantile fibrosarcoma, desmoid tumors (or aggressive fibromatosis), angiomatoid malignant fibrous histiocytoma, dermatofibrosarcoma, and hemangiopericytoma (in infants and young children). Infantile (congenital) fibrosarcoma is distinguished by its age of onset. Tumors which develop in children less than 5 years of age have a more benign behavior and are typically managed surgically. A fibrosarcoma that develops in older children is akin to adult-type soft tissue sarcoma. Desmoid tumors are locally infiltrating tumors with no metastatic risk. Surgical control can be difficult depending on location of the tumor, as the need to preserve normal structures is extremely important. There is a high potential for local recurrence after surgical resection alone but overall has a highly variable natural history, including the potential for spontaneous regression. Mutations in exon 3 of the beta-catenin gene are seen in over 80 % of tumors. In treating these lesions with radiotherapy, gross versus microscopic tumor is controlled equally well using 50-60 gray (Gy) [50] . Additionally, chemotherapy with sunitinib has been shown to have some efficacy [51] , in addition to other chemotherapy regimens used in order to avoid the toxicity of high dose radiotherapy in a child.
Treatment principles
Aside from the aforementioned low-grade pediatric sarcomas that may be treated with surgery alone, the majority of NRSTS may be considered to have adult-like soft tissue sarcoma biologic characteristics. Of course exceptions exist, for example, embryonal sarcoma of the liver as a distinctive and rare pediatric cancer now often included under the NRSTS rubric. It is now differentiated from biliary rhabdomyosarcomas and has unique therapeutic challenges [52] [53] [54] . But in general, optimal therapeutic management of pediatric NRSTS requires a multi-disciplinary approach, with surgical resection, radiotherapy, and chemotherapy utilized as individual or combined therapy. Surgical resection is an important component of management for most soft tissue sarcomas. As in adults with extremity soft tissue sarcomas, less than 10 % of patients undergo amputation. A wide, en bloc excision (>1-2-cm margins) is acceptable for low-grade, T1a lesions, while conservative surgery plus radiotherapy is the standard for all other STSs with an overall local control of 85-90 %. For patients presenting with localized, low-grade tumors, complete surgical resection alone (if able to obtain margins that are tumor-free) or re-excision if original margins were positive is typically utilized. In cases where tumor margins are positive and further resection is not feasible, postoperative radiotherapy or brachytherapy should be considered. The COG From Guillou et al. [89] MPNT malignant peripheral nerve tumor, PNET primitive neuroectodermal tumor, MFH malignant fibrous histiocytoma ARST0032 trial for low-grade NRSTS divides patients into two separate clinical groups. Clinical group I underwent definitive surgical resection followed by no radiotherapy and clinical group II undergoes definitive surgical resection followed by radiotherapy to a total dose of 55.8 Gy if it is deemed that a local recurrence would result in significant morbidity. A note is made that this is a lower radiation dose than in adult practice in which retrospective reviews show that postoperative radiation doses in the 60-66-Gy range is optimal [55] . Management of localized, high-grade NRSTS again utilizes complete surgical resection alone for small tumors, if all margins are negative after initial resection or additional re-excision in the setting of an initial marginal resection with positive margins. This differs in stark contrast to adult STS practice in which adjuvant radiotherapy is felt to be beneficial for improved local control. We await follow-up data from the recently closed COG ARST0032 trial to see if this subset of patients has an excessive local recurrence rate. But, similar to low-grade tumors, postoperative radiotherapy or brachytherapy is recommended if tumor margins are positive and further resection is not possible. In the setting of complete excision with negative tumor margins, the size of the tumor influences the use of adjuvant therapy. Furthermore, the use of preoperative radiotherapy in NRSTS has been infrequent.
More specifically in COG ARST0032, adjuvant therapy after definitive surgical resection was determined by tumor size.
Those patients with tumors greater than 5 cm went on to receive postoperative radiotherapy to a total dose of 55.8 Gy as well as five cycles of ifosfamide and doxorubicin chemotherapy. Those patients with tumors less than 5 cm were divided based upon whether a fascial plane was disrupted during the surgical resection. Patients with an unbroken fascial plane did not receive radiotherapy, while those with a broken fascial plane receiving adjuvant radiotherapy to a total dose of 55.8 Gy.
The actual evidence for postoperative radiotherapy after surgical resection in NRSTS is sparse but has been nicely reviewed by Million and Donaldson [56] . The POG protocol 8653 intended to study the role of adjuvant radiotherapy in children with surgically resectable NRSTS [10] . Local therapy was standardized to consist of surgery alone for patients (n055 patients) with complete resection with surgical margin defined as a "cuff of normal tissue." Those with marginal resections or positive margins (n025 patients) were to receive radiotherapy using doses that were age adjusted: under age 6 received 35 Gy with an additional 10 Gy boost, while older patients received 45 Gy with a 5-Gy boost. Protocol guidelines were improperly followed, but results indicate higher local control rates with radiotherapy for marginal excisions in high-grade tumors [57] . Specifically, of those patients with high-grade tumors, there were six out of 26 local failures with surgery alone compared to one out of 13 local recurrences for surgery and radiotherapy. Moreover, the POG grade 3 patients had a 52 % survival at 5 years compared to the POG grade 1-2 patients with a 92 % 5-year survival. In addition, four retrospective reviews of the St. Jude Children's Research Hospital experience with NRST considered the role of adjuvant radiotherapy [3, [42] [43] [44] 58] . In totally, resected disease (clinical group I), postoperative radiotherapy appeared to reduce local recurrence only in high-grade disease. Furthermore, in patients with positive surgical margins (clinical group II), radiotherapy reduced local recurrences (p<0.001). These findings are of critical importance because there will be many clinical situations in which radical surgery is not possible or is possible and refused secondary to unacceptable functional, cosmetic, or psychological consequences. In these patients, radiotherapy may play a crucial role by allowing more conservative surgery with similar rates of local control.
Investigators from the University of Florida have reported on 95 NRSTS patients, including those who were young adults who had resectable disease that was managed with either preoperative radiotherapy (RT) to a median dose of 50.4 Gy or postoperative RT to a median dose of 61 Gy [59] . Overall local control was 12 % at 5 years. Patients with close or positive margins defined as less than 1 cm had local recurrences in eight out of 30 patients (27 %) compared to four out of 64 patients (6 %) with negative margins. There were no associations based on grade, but as this was not a randomized trial, low-grade tumors tended to not be irradiated in Total score 6, 7, or 8
Modified from Guillou et al. [89] MFH malignant fibrous histiocytoma, HPF high-power field comparison to high-grade tumors. Finally, all local recurrences lead to ultimate death of the patient. Treatment of advanced disease presents a unique clinical challenge. For those patients with locally advance tumors, multimodality therapy is utilized. The role of chemotherapy is beyond the scope of this review. Adjuvant chemotherapy in pediatric NRSTS was originally defended on the basis of the significant risk of metastatic disease and local recurrence in high-grade lesions, retrospective comparisons, and the success of chemotherapy in rhabdomyosarcoma. The most active single agents are doxorubicin and ifosfamide [60] . Other active agents are dacarbazine, actinomycin D, vincristine, etoposide, and cyclophosphamide [3, 12, 33, 35, 36, [61] [62] [63] . But, increasing certain histologies of NRSTS are being recognized as being more chemosensitive. Combinations of doxorubicin and ifosfamide or gemcitabine and Taxol are increasing being utilized. Integration with concurrent radiotherapy is problematic for certain drugs such as doxorubicin, which may markedly increase acute toxicities such as skin reactions. But, increasingly, the role of preoperative chemo-and radiotherapy is being explored. Metastatic disease tends to be treated with chemotherapy in the adult population with more reliance on surgical resection in NRSTS. In these cases, chemotherapy and radiation therapy are utilized for residual or high-grade disease.
For those patients presenting with oligometastatic pulmonary disease, surgical resection of metastases should be considered, and the use of stereotactic radiosurgery needs further investigation. COG ARST0032 approached metastatic disease based on initial tumor grade. For high-grade tumors, patients were then divided into two groups, grossly resected versus unresected, where they received adjuvant chemotherapy plus radiotherapy versus neoadjuvant chemoradiotherapy, respectively. For low-grade tumors, if all disease was resected, independent of microscopic margin status, these patients went on to observation alone. If all disease was not resected, they entered in the high-grade arm of the algorithm where further therapy was assigned.
Ferrari et al. (2011) published a retrospective pooled analysis from the US and Europe investigating prognostic variables and treatment modalities in 304 patients with initially unresectable but nonmetastatic NRSTS (akin to rhabdomyosarcoma clinical group III) [64] . This study noted that there was similar negative prognostic implication of particular tumor characteristics compared to adult soft tissue sarcoma, with those poor prognostic features including large tumor size, MPNST histology, older patient, and axial location of tumor. When examining response rate to chemotherapy, a 41 % response rate was recorded (in terms of complete response and major partial response). This was 57 % if minor responses were included. In addition, it was reported that final outcome was directly correlated with response to initial chemotherapy. Particular importance of local therapy was also emphasized in this study, as local progression and relapse was the major cause of treatment failure and patients able to undergo complete delayed resection had the best outcome. From a radiotherapy perspective, the use of radiotherapy also was directly correlated with a better survival on multivariate analysis. It was noted that radiotherapy improved survival after incomplete resection, but had little or no benefit after complete surgery. However, the authors do describe a selection bias for those patients who received radiotherapy, as these patients were a selected subset with unfavorable features. Furthermore, the use of radiotherapy was not homogeneous and was highly variable over time between centers included in the study. Radiotherapy was the only local modality in 72 patients. An additional 72 patients underwent surgery and radiotherapy with the vast majority undergoing radiotherapy postoperatively. The median total radiation dose was 54 Gy for patients receiving RT alone or postoperative RT for positive margins. Patients who had a complete surgical resection and who received RT had a median radiation dose of 50 Gy. Overall, this study concluded that aggressive multimodal treatment strategies should be pursued with effort to get a patient to a complete surgical resection. This study has also pointed out that there are histology-specific predictors of chemotherapy response seen in other studies, which in turn impact on prognosis. Specifically, synovial cell sarcoma is a relatively chemosensitive tumor while malignant peripheral nerve sheath tumor tended to be more chemoresistant. Investigators at COG in designing future NRSTS studies are contemplating using preoperative chemoradiation for locally advanced tumors in which lower radiation doses will be justified if there is a good response to chemotherapy or in the case of chemosensitive histologies.
Another University of Florida study focused on unresectable, nonmetastatic NRSTS patients that documented relatively poor results associated with radiotherapy and chemotherapy [65] . Of the 19 patients in this small study, the median radiation dose was 55.2 Gy, 12 patients received chemotherapy, and 13 patients had high-grade tumors. The 5-year local control rate was only 40 %. Nine of the 13 recurrences were local only, but all recurrences ultimately resulted in patient death, half of whom never developed metastatic disease. This study highlighted the need for more intensive therapies aimed at improving local control for unresectable NRSTS.
Radiotherapy
Radiotherapy for pediatric NRSTS may be delivered after biopsy, but before definitive surgery (preoperatively), postoperatively, intraoperatively, or as definitive therapy. The arguments for preoperative over postoperative irradiation include the following. First, preoperative treatment will produce partial regression of the tumor, and the resection may be less extensive than if the surgery had been done first. Second, preoperative treatment may decrease the risk of autotransplantation of the tumor in the surgical bed and may also decrease the risk of intravascular seeding. Third, in preoperative treatment, the clinically and radiographically demonstrable areas of risk are treated while other tissues are protected [66, 67] . In addition, because postoperative treatment must cover all surgically manipulated areas, the volume receiving radiotherapy is quite often much larger. Finally, the postoperative surgical bed may be poorly vascularized, so the concern regarding tumor cell hypoxia in this setting has led to the requirement of higher radiation doses. Results of the Canadian randomized trial in adult STS (discussed further below) suggest an equivalence of 50 Gy preoperatively to 66-70 Gy postoperatively [68] .
When determining proper radiotherapy treatment margins, it is important to remember that margins do not cross uninvolved bone or fascia that is not breached by tumor. Margins may be relatively tight for low-grade lesions. Historically, radiation field treatment margins have been quite large (5-10 cm) for adult, high-grade extremity STS, but may be able to be decreased. MRI imaging may play a critical role in establishing of proper tumor margins for adult STS and for NRSTS by extrapolation. White and colleagues performed a histologic assessment of peritumoral edema in soft tissue sarcoma [69] . In this study, they sought to evaluate whether satellite tumor cells could be identified in the tissues surrounding a soft tissue sarcoma and whether their presence correlated with T2 signal on MRI. Fifteen patients with high-grade extremity and truncal soft tissue sarcoma underwent preoperative MRI and 12 of these patients received gadolinium contrast. The extent of the T2 signal was then determined, and the presence of tumor cells in the surrounding tissues of pathologic specimens was correlated with the MRI findings. None of the patients underwent preoperative chemotherapy or radiotherapy. The maximal tumor size for patients in this study was 13.8 cm (mean value). The extent of peritumoral T2 signal was 2.5 cm and the extent of peritumoral contrast enhancement was 1.1 cm. Of note, the maximal length of T2 signal was usually in the superior-inferior direction. It was noted that tumor cells were present beyond the tumor margin in ten of the 15 cases. In six of these cases, tumor cells were <1 cm from the tumor margin while, in four cases, tumor cells were located 1-4 cm from the tumor margin. There were 88 anatomic regions available for histologic evaluation. Krasin and colleagues have reported on a small series of 32 high-grade NRSTS cases in which 2-cm margins around gross tumor volumes were chosen [70] . Median doses for preoperative and postoperative radiotherapy were 45 and 60 Gy, respectively. The 3-year local recurrence rate was 4 %. Local recurrences were in the high dose radiation volume and correlated with those patients who had marginal resections.
As previously mentioned, one of the primary goals in the treatment of NRSTS is to maximize tumor control, while preserving function. Therefore, careful consideration of the benefits and complications secondary to preoperative versus postoperative radiotherapy should be carefully considered. Preoperative radiotherapy requires smaller field sizes and lower doses, but is also associated with higher rates of wound complications. However, long-term complications may be better with smaller doses and smaller fields. Pisters et al. (2007) describe the "trade-off" between preoperative versus postoperative radiotherapy highlighting the particular issues associated with these two modalities [71] .
Furthermore, O'Sullivan and colleagues performed a prospective randomized trial in which they aimed to determine whether the timing of external beam radiotherapy affected the frequency of wound healing complications in soft tissue sarcoma of the limbs [68] . This randomized trial by the NCI Canada included 190 patients enrolled between 1994 and1997. Eligible patients included those who had limb soft tissue sarcoma without the presence of metastasis. Patients were stratified according to tumor size, ≤10 cm or >10 cm, and then randomized to receive preoperative radiotherapy consisting of 50 Gy in 25 fractions with a 16-20-Gy postoperative boost in the setting of positive surgical margins (94 patients) versus postoperative radiotherapy consisting of 66 Gy in 33 fractions (96 patients). Surgery and radiotherapy were separated by 3-6 weeks in both groups. Primary endpoint was frequency of wound complications within 120 days of surgery and secondary endpoints included local control, development of distant metastases, progression-free survival, and overall survival. The trial had to be closed prematurely before reaching its accrual goal of 266 patients secondary to an interim analysis which showed significantly different outcomes. The median follow-up was 3.3 years. Fourteen patients in the preoperative radiotherapy group had positive surgical margins and ten underwent postoperative radiotherapy boost. The median field size was 333 cm 2 in the preoperative group and 416 cm 2 in the postoperative group (p00.01). Overall, 35 % of the patients in the preoperative group suffered wound complications compared to 17 % in the postoperative group. In addition, there was no difference between groups in rates of local recurrence, regional/distant recurrence, or progression-free survival. Overall survival was slightly higher in the preoperative versus postoperative group (p00.0481), but the study was not powered to look at survival. Davis et al. (2005) examined late radiation morbidity in patients randomized to preoperative versus postoperative radiotherapy for extremity soft tissue sarcoma [72] . This NCIC study enrolled 129 patients, and morbidity was evaluated at a single time-point: 2 years. Functional status was assessed using the Musculoskeletal Tumor Society Salvage Score (MSTS) in which the clinician rated pain, strength, joint stability, range of motion, and global function, as well as the Toronto Extremity Salvage Score (TESS) in which the patient evaluated difficulties in performing ADLs, self-care, and mobility. Furthermore, fibrosis and joint stiffness were evaluated using the EORTC/RTOG Late Radiation Toxicity Criteria and edema was evaluated using Stern's Rating Scale for Edema. Results indicated that patients treated with postoperative radiotherapy tended to have greater subcutaneous fibrosis (48 % vs. 32 %, p 00.07) with no statistically significant different between groups for amount of joint stiffness or edema. Furthermore, there was no statistically significant difference in function between the two groups for either the MSTS or TESS scores (p00.08 and 0.17, respectively). Of note, radiotherapy field size was predictive or greater rates of fibrosis (p00.002), joint stiffness (p00.006), and marginally predictive of edema (p00.06). Also, the 6.9-year median follow-up data were presented at the American Society for Clinical Oncology 2004 Annual Meeting and grade 2-4 toxicity was noted to be 68 % in the preoperative group versus 86 % in the postoperative group (p00.002).
A common conundrum occurs when patients undergoing preoperative radiotherapy are found to have close or positive surgical margins when they ultimately undergo surgery. While such microscopic tumor residua in the surgical bed may still be destined to die from the prior effects of radiotherapy, postoperative radiotherapy has historically been a consideration. Recent data from the Canadian investigators, however, suggest that there is little benefit to this practice of delivering a postoperative boost [73] .
Brachytherapy may play an important role in limbsparing surgery for NRSTS [74] . Brachytherapy is often, but not always, combined with pre-or postoperative external beam treatment. Potential advantages of brachytherapy include: its radiobiologic effectiveness, which is increased by the delivery of a high dose of radiotherapy over a few days rather than several weeks; concentrated dose given deep within the tumor bed; increased sparing of the surrounding normal tissue and overlying skin secondary to the rapid reduction of dosage; and the convenience of shorter treatment time [75] [76] [77] . A more detailed exploration of the use of brachytherapy in low-grade tumors was pursued at MSKCC because their original randomized trial did not include a large number of patients with low-grade NRSTS. From 1982 to 1992, 45 patients with low-grade tumors were randomized to brachytherapy versus observation. There was no benefit to brachytherapy in terms of local recurrence (approximately 76 % local control in each arm, p00.60) or overall survival (p00.38) [78] .
Furthermore, in two additional studies, patients with high-grade NRSTS with negative margins had a local control rate of 89 % and 94 %, respectively, when treated with brachytherapy, compared to 59 % versus 77 % in those with positive margins. In patients with high-grade tumors and positive margins treated with brachytherapy and external beam radiotherapy, the local control rate was 90 % [78] [79] [80] . From the investigators' point of view, these two randomized trials argue in favor of adjuvant brachytherapy for resected high-grade tumors, surgery alone in the treatment of resected low-grade tumors <5 cm, and for consideration of postoperative external beam radiotherapy for resected low-grade tumors >5 cm because of the remaining high risk of local recurrence in these tumors (i.e., 20-25 %). Early in the MSKCC trials, there was a significantly higher rate of wound complications in patients treated with brachytherapy compared to observation (44 % vs. 14 %, p00.0006). The higher rate of complications has been improved by a guiding principle of not loading patients with radioactivity until the fifth postoperative day [81] .
Newer external beam modalities offer the potential for better sparing of normal tissues and hence an improvement in the therapeutic ratio. The use of intensity modulated radiotherapy to better conform the high dose radiation distribution to the tumor region may well reduce developmental toxicities, but comes with the theoretical problem of increased integral dose which may increase the later risk for secondary cancers [82, 83] . Image guidance techniques improve the accuracy of radiotherapy delivery and may prove useful to further reduce radiotherapy treatment margins. Particle therapy, such as protons, is enthusiastically under investigation and has shown preliminary benefit in Ewing's sarcoma and rhabdomyosarcomas [84] [85] [86] .
Conclusions
Overall, the treatment approach to pediatric NRSTS should have a multimodality focus. When considering the use of radiotherapy, careful thought of many patient characteristics and tumor factors must be reviewed in order to provide the best treatment plan. Certain lowgrade, small tumors are well managed with surgery alone. But, as we have described in this review, preoperative radiotherapy, although it has a propensity for greater frequency of perioperative wound complications over postoperative radiotherapy (larger volumes, higher doses), can lead to less long-term morbidity. Furthermore, we emphasized the importance of using tighter radiotherapeutic treatment margins including regions of peritumoral edema identified on MRI to aid in the design of treatment fields. More consideration for preoperative external beam radiotherapy in the treatment of their NRSTS needs to be considered, especially for those patients with high-risk features, where possible. And the future use of newer radiation modalities such as proton radiotherapy and selected use of brachytherapy may help to reduce toxicities.
